Whalesbook
Pfizer's FY26 Financial Update
Pfizer Ltd has reported its financial results for the fiscal year ended March 31, 2026. The company posted a net profit of ₹722.43 crore for the full year, with revenue increasing by 10.35% to ₹2,707.60 crore.
In the fourth quarter ending March 31, 2026, net profit stood at ₹199.82 crore. This quarterly result was affected by ₹49.16 crore in exceptional charges. These charges included ₹41.73 crore for personnel separation costs related to a supply agreement with Cipla Limited, and an additional ₹7.43 crore for new labor code provisions. Despite these charges, quarterly total income grew 5.26% year-on-year to ₹669.95 crore.
The annual net profit of ₹722.43 crore is lower than the prior year's ₹767.60 crore. This difference is primarily due to a significant one-time gain of ₹172.81 crore from land and building sales recorded in the previous fiscal year, which did not repeat.
Factors Affecting Profitability
Pfizer's core business operations are demonstrating steady revenue growth, as shown by the 10.35% increase for the fiscal year. The year-on-year profit comparison is influenced by non-recurring items, including the current year's exceptional charges and the absence of a large prior-year asset sale gain. The strategic manufacturing and supply agreement with Cipla Limited has introduced temporary costs associated with personnel adjustments during this transition phase.
Shareholder Returns and Financial Health
The company's strong financial standing is underscored by its minimal debt and substantial cash reserves. Total equity stands at ₹4,202.90 crore, with borrowings at a mere ₹2.50 crore as of March 31, 2026. Given this robust balance sheet, the Board has recommended a final dividend of ₹75 per share (750%). A clean audit opinion from statutory auditors also provides assurance on the reliability of its financial reporting.
Risks and Peer Context
Investors will monitor the ongoing financial impact of the exceptional charges, particularly those linked to the Cipla agreement, and the continued base effect on year-on-year profit comparisons due to the prior year's land sale gain.
Pfizer's 10.35% annual revenue growth is a solid performance in the competitive Indian pharmaceutical sector. For perspective, Abbott India reported FY25 revenue of ₹5,483 crore and Cipla reported FY25 revenue of ₹29,069 crore. While Pfizer's reported annual profit decreased due to specific one-off events, its core revenue generation remains competitive.
What to Watch Next
Looking ahead, key areas for investors to track include the successful integration of the Cipla manufacturing and supply agreement and its financial outcomes. Sustaining current revenue growth momentum into the next fiscal year will be important, alongside management commentary on future strategies and margin outlook. The company's utilization of its strong cash reserves and dividend distribution policies will also be closely watched.